Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF

Rhea-AI Summary

As of December 31, 2021, IPSEN's liquidity agreement with NATIXIS ODDO BHF reported a liquidity account holding 34,053 shares and €1,433,400.74. Initially, 12,751 shares and €3,137,935 were allocated when the agreement commenced. Between July 1 and December 31, 2021, a total of 1,350 buy and 1,425 sell transactions occurred, with trading volumes of 178,366 shares (€15,275,528.42) bought and 168,568 shares (€14,644,572.90) sold. IPSEN is a global biopharmaceutical company focused on Oncology, Neuroscience, and Rare Diseases, with sales exceeding €2.5bn in FY 2020.

Positive

• Increased liquidity account from initial resources; 34,053 shares and €1,433,400.74 reported as of 12/31/2021.
• Strong trading activity with 1,350 purchase and 1,425 sell transactions during the reporting period.

Negative

• None.

BOULOGNE-BILLANCOURT, France--(BUSINESS WIRE)-- Regulatory News:

Under the liquidity agreement entrusted by IPSEN to NATIXIS ODDO BHF, as of December 31, 2021, the following resources were included to the dedicated liquidity account:

• 34,053 shares
• €1,433,400.74

It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:

• 12,751 shares
• €3,137,935

Between July 1^st, 2021 and December 31, 2021 have been executed:

• 1,350 purchase transactions
• 1,425 sell transactions

Under the same period, the volumes traded represented:

• 178,366 shares and €15,275,528.42 to the purchase
• 168,568 shares and €14,644,572.90 to the sell

Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Neuroscience and Rare Disease; it also has a well-established Consumer Healthcare business. With Total Sales of over €2.5bn in FY 2020, Ipsen sells more than 20 medicines in over 115 countries, with a direct commercial presence in more than 30 countries. The Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has c.5,700 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit www.ipsen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220117005374/en/

Investisseurs

Craig Marks

Vice President, Investor Relations

+44 7584 349 193

Adrien Dupin de Saint-Cyr

Investor Relations Manager

+33 6 64 26 17 49

Media

Gwenan White

Executive Vice President, Communications and Public Affairs

+44 7876 391 429

Fanny Allaire

Global Communications Director

+ 33 6 08 91 92 55

Source: IPSEN

FAQ

What are the liquidity account details for IPSEN as of December 31, 2021?

As of December 31, 2021, IPSEN's liquidity account contained 34,053 shares and €1,433,400.74.

How many transactions were executed by IPSEN between July 1 and December 31, 2021?

IPSEN executed a total of 1,350 purchase and 1,425 sell transactions during this period.

What was the total volume of shares traded by IPSEN in the second half of 2021?

In the second half of 2021, a total of 178,366 shares were bought and 168,568 shares were sold by IPSEN.

What financial performance did IPSEN achieve in FY 2020?

IPSEN reported total sales exceeding €2.5 billion in FY 2020.